November 5, 2021 10:34 AM EDTUpdated 10:50 AM
Pharma
FDA+

Dem­s' $100B deal re­duced fur­ther: Medicare drug price ne­go­ti­a­tions pushed to 13 years for bi­o­log­ics

Zachary Brennan

Senior Editor

House De­moc­rats are on the cusp of pass­ing two ma­jor pieces of Biden’s agen­da Fri­day, but Medicare drug price ne­go­ti­a­tions — once the cen­ter­piece of the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

A service from the Financial Times